Reimagining Cell Lines For AAV Manufacturing: Tackling Encapsidated Host Cell DNA To Improve Quality

By H Kewes, T Bauer, T Bonifert, J Drushku, and M Hussong

The ELEVECTA™ producer cell line represents a groundbreaking advancement in the production of recombinant adeno-associated virus (rAAV), streamlining the manufacturing process while enhancing safety. This innovative platform eliminates the need for transient transfection or helper viruses, significantly reducing the encapsidation of host cell DNA (hcDNA) within rAAV particles. Such a reduction is critical, as encapsidated DNA poses potential immunogenic and oncogenic risks for patients receiving gene therapy.

The ELEVECTA cells, derived from HEK293 or CAP™ lines, thrive in animal component-free media and can be adapted to various bioreactor configurations. By enabling the synthesis and packaging of ITR-flanked vector genomes into viral capsids with minimal variability, the ELEVECTA system facilitates straightforward scaling of production. This advancement not only aligns with FDA regulatory standards but also ensures enhanced rAAV purity without compromising cell viability.

To learn more access the full poster.